The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1573-7217

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer ; volume:197 ; number:2 ; day:19 ; month:11 ; year:2022 ; pages:319-331 ; date:1.2023
Breast cancer research and treatment ; 197, Heft 2 (19.11.2022), 319-331, 1.2023

Creator: Bardia, Aditya
Mayer, Ingrid
Winer, Eric
Linden, Hannah M.
Ma, Cynthia X.
Parker, Barbara A.
Bellet, Meritxell
Arteaga, Carlos L.
Cheeti, Sravanthi
Gates, Mary
Chang, Ching-Wei
Fredrickson, Jill
Spoerke, Jill M.
Moore, Heather M.
Giltnane, Jennifer
Friedman, Lori S.
Chow Maneval, Edna
Chan, Iris
Jhaveri, Komal

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10549-022-06797-9

URN: urn:nbn:de:101:1-2023031523010576462831

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:51 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Bardia, Aditya
Mayer, Ingrid
Winer, Eric
Linden, Hannah M.
Ma, Cynthia X.
Parker, Barbara A.
Bellet, Meritxell
Arteaga, Carlos L.
Cheeti, Sravanthi
Gates, Mary
Chang, Ching-Wei
Fredrickson, Jill
Spoerke, Jill M.
Moore, Heather M.
Giltnane, Jennifer
Friedman, Lori S.
Chow Maneval, Edna
Chan, Iris
Jhaveri, Komal
SpringerLink (Online service)

Other Objects (12)

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Related objects

Reset password